Overview
Boruzu is approved by the U.S. Food and Drug Administration (FDA) for treating adults with multiple myeloma. It may be used as an initial treatment or as part of retreatment if the disease returns. Eligibility generally requires a confirmed diagnosis of multiple myeloma, and Boruzu may be given alone or in combination with other medicines, depending on the treatment plan.  Boruzu is also known by its drug name, bortezomib.

Boruzu is a proteasome inhibitor. It works by blocking proteasomes (cell structures that break down unneeded proteins). In multiple myeloma cells, this causes proteins to build up, disrupting cell function and leading to cell death.

How do I take it?
Prescribing information states that Boruzu is given either as a short intravenous (into a vein) injection or as a subcutaneous (under the skin) injection. The dosing schedule for multiple myeloma is determined by the healthcare provider and may include repeated cycles of treatment. Retreatment can begin at the last tolerated dose if the disease returns. Boruzu should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Boruzu include nausea, diarrhea, thrombocytopenia (low platelet count), neutropenia (low level of neutrophils, a type of white blood cell), peripheral neuropathy (nerve damage that can cause numbness, tingling, or pain in the hands and feet), fatigue, neuralgia (nerve pain), anemia (low red blood cell count), leukopenia (low white blood cell count), constipation, vomiting, lymphopenia (low lymphocyte count), rash, pyrexia (fever), and anorexia (loss of appetite).

Rare but serious side effects may include severe peripheral neuropathy, hypotension (low blood pressure), cardiac toxicity (heart damage or worsening heart failure), pulmonary toxicity (lung damage or acute respiratory syndromes), posterior reversible encephalopathy syndrome (a neurological condition that can cause headaches, confusion, and vision problems), severe gastrointestinal toxicity, severe thrombocytopenia and neutropenia, tumor lysis syndrome (a dangerous metabolic complication), hepatic toxicity (liver damage), thrombotic microangiopathy (damage to small blood vessels leading to organ injury), and embryo-fetal toxicity (risk of harm to an unborn baby).

For more information about this treatment, visit:
Boruzu (Bortezomib) Injection, for Subcutaneous or Intravenous use — Amneal Pharmaceuticals